Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sentinel Pilot Begins Scanning Drug Data, But Device Work Still Exploratory

This article was originally published in The Gray Sheet

Executive Summary

FDA will implement its mini-Sentinel post-market safety surveillance program for the first time, using data from an ongoing randomized trial of a diabetes drug.
Advertisement

Related Content

Cap On Mini-Sentinel Funds Raised To $135 Mil. To Support Powerful Surveillance Resource
CDRH Seeks To Expand Public-Private Medical Device Epidemiology Network
Draft User Fee Bills Aim To Streamline And Strengthen Device Regs
Regulatory News In Brief
Regulatory News In Brief
Institute Of Medicine On 510(k) Review Program: Dump It
Institute Of Medicine On 510(k) Review Program: Dump It
Onglyza Data From Sentinel Pilot Can Be Validated By Phase IV Trial, FDA Says
Automated Device Safety Surveillance Gets Proof Of Principle
Advertisement
UsernamePublicRestriction

Register

MT029792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel